Vanguard Personalized Indexing Management LLC Reduces Holdings in Nkarta, Inc. $NKTX

Vanguard Personalized Indexing Management LLC lowered its stake in shares of Nkarta, Inc. (NASDAQ:NKTX) by 30.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 28,030 shares of the company’s stock after selling 12,333 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in Nkarta were worth $47,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Wealth Enhancement Advisory Services LLC bought a new stake in Nkarta in the first quarter worth $32,000. CWM LLC increased its position in Nkarta by 3,437.3% during the first quarter. CWM LLC now owns 28,157 shares of the company’s stock valued at $52,000 after acquiring an additional 27,361 shares during the last quarter. Cerity Partners LLC bought a new position in Nkarta during the first quarter valued at $55,000. Deutsche Bank AG increased its position in Nkarta by 36.3% during the first quarter. Deutsche Bank AG now owns 58,812 shares of the company’s stock valued at $108,000 after acquiring an additional 15,655 shares during the last quarter. Finally, Ieq Capital LLC bought a new position in Nkarta during the first quarter valued at $117,000. Institutional investors own 80.54% of the company’s stock.

Nkarta Trading Down 2.5%

Shares of NASDAQ:NKTX opened at $2.35 on Tuesday. The business has a 50-day moving average price of $2.18 and a 200 day moving average price of $2.00. The company has a market capitalization of $166.92 million, a price-to-earnings ratio of -1.59 and a beta of 0.86. Nkarta, Inc. has a 12-month low of $1.31 and a 12-month high of $3.81.

Nkarta (NASDAQ:NKTX) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.06. As a group, equities research analysts predict that Nkarta, Inc. will post -1.7 earnings per share for the current fiscal year.

Analyst Ratings Changes

NKTX has been the subject of several analyst reports. Stifel Nicolaus decreased their price target on shares of Nkarta from $14.00 to $12.00 and set a “buy” rating for the company in a research report on Thursday, August 14th. Needham & Company LLC restated a “buy” rating and issued a $10.00 price target on shares of Nkarta in a report on Wednesday, August 13th. Weiss Ratings restated a “sell (e+)” rating on shares of Nkarta in a report on Wednesday, October 8th. Finally, Wall Street Zen upgraded shares of Nkarta from a “sell” rating to a “hold” rating in a report on Saturday. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $13.50.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.